Introduction
Approximately 20% of the adult epilepsy population has learning disabilities (LD), and the occurrence of epilepsy increases with the severity of LD. 1 The chances of achieving seizure control in patients with epilepsy and LD is poorer than in those without LD, with 45% of epilepsy patients with LD being refractory to antiepileptic drugs (AEDs), as compared with approximately 30% of the total epilepsy population.
2,3
The most difficult-to-control epilepsies are found in this subpopulation. For example, in epileptic encephalopathies, such as Lennox-Gastaut syndrome and Dravet syndrome, the seizures are mostly pharmacoresistant. 4, 5 Nevertheless, many of these patients have a heavy drug burden despite the fact that individuals with LD appears to be more prone to central nervous side effects from AEDs than those without LD. 6, 7 Patients with epilepsy and LD are a very heterogeneous patient group necessitating that the treatments are tailored to every individual patient, with the aim of obtaining an optimal balance between seizure reduction and side effects. Vagus nerve stimulation (VNS) is an established treatment option that is offered to patients with drug-resistant seizures and who after evaluation are not candidates for epilepsy surgery. The seizure-reducing effect of VNS may increase gradually over 18-24 months of treatment. 8 In a prospective 3-year follow-up study of adult patients more than 50% seizure reduction was reported in 43% of the patients. 9 Additionally, other studies have described subjective improvements in various quality-of-life measurements during VNS treatment, independent of the effect on the seizure frequency. [10] [11] [12] Sideeffects of VNS treatment are mainly stimulation-related and tend to decrease over time.
A non-pharmacological treatment like VNS is to be warmly welcomed in patients with severe epilepsy and LD. However, it is not evident that persons with LD obtain the same seizure-reducing effect from VNS treatment as persons without LD. Responder rates (i.e. those having more than 50% seizure reduction) varying from 28% to 68% have been reported. 13, 14 The purpose of this open, uncontrolled, retrospective study was to analyze the efficacy and tolerability of VNS treatment in Norwegian patients with drug-resistant epilepsy and LD. We also wanted to explore the efficacy of VNS in different sub-groups of these patients.
Materials and methods
All those patients aged 14 years or older, and with a combination of LD and epilepsy, who had had a VNS implantation at The National Hospital in Oslo in the period between October 1997-May 2008 were included in the study. All the patients had been followed up at The National Centre for Epilepsy, located just outside Oslo, and their demographic and electroclinical data were retrospectively obtained from the patients' medical records at the centre. Patients' epilepsies were classified according to the recommendations of the International League Against Epilepsy in 1989. 15 Each patient had been diagnosed with learning disability, graded as either mild (IQ 50-70), moderate (IQ 35-49), severe (IQ 20-34), or profound (IQ < 20). 16 The patients and their caregivers were contacted and asked to complete a questionnaire. Two patients had died during the follow-up period, and their relatives were not contacted regarding the questionnaire. Based on the medical records, the patients' seizure diaries, and the information given by the caregivers, the patients' seizure types, frequencies, and durations, their postictal condition, and their overall well-being were assessed both over a 6-month baseline period prior to VNS implantation, and also in the follow-up period after the implantation.
VNS stimulation parameters
The VNS was started 1-2 days after the operation with quick ramp-up procedure. The standard initial parameters were: output current (OC) 0.25 mA, frequency 20 Hz, pulse width 250 ms, on-time 30 s, and off-time 5 min. The OC was increased by 0.25 mA every other day up to 1 mA, if the stimulation was well-tolerated. Follow-up visits were usually every three months. The parameters were adjusted individually according to the effect and tolerance, and changes in on-off parameters were attempted in those who experienced no reduction in seizure frequency.
Results
50 patients fulfilled the inclusion criteria. Due to local infection, in two patients the devices were explanted after 5 and 8 months, respectively. Excluding these two patients, the mean follow-up period was 4.6 years (range: 1.3-11.9 years). For five patients, the devices were explanted due to lack of efficacy. One patient died during the follow-up period from a disease unrelated to the epilepsy. Another patient died in sudden unexpected death in epilepsy (SUDEP). Thus, the discontinuation rate of the patient group was 18%.
The generator was replaced in eight patients due to end of battery life, and three of these patients have now received their third generator.
Out of 48 caregivers, 34 (71%) completed and returned the questionnaire. Table 1 summarizes the demographic and clinical features of the patients.
Surgical complications
Two patients developed local infections necessitating device removal. In one patient with tuberous sclerosis complex (TSC) the operation was unusually prolonged, and the patient woke from anaesthesia with a unilateral central facial palsy. This could have been due to a thromboembolic episode, although a CT scan did not reveal a cerebral infarction. The facial palsy ameliorated after about 6 months.
AED treatment
Out of 48 patients, 29 (63%) changed their drug treatment (type of AED and/or dosage) during the follow-up period. Before implantation the patients were taking an average of 2.4 AEDs, and this number was unchanged at follow-up.
Effect on seizure frequency
At follow-up, none of the patients was seizure-free. Twelve patients (25%) had more than 50% reduction in seizure frequency, i.e. they were therapy responders, while 22 patients (46%) had a reduction in seizure frequency, but less than 50% compared with baseline frequency. In 14 patients (29%) the seizure frequency did not change. Table 2 shows the effects of VNS treatment on seizure frequency in different sub-groups of the patients. Unfortunately, these subgroups are too small to allow evaluation of which disorders benefited most from VNS treatment. However, there was a tendency for a better effect in patients with LennoxGastaut syndrome than in the rest of the population (38% responders in the Lennox-Gastaut syndrome group compared with 25% in the whole population). Likewise, it was not possible to draw firm conclusions about predictive factors regarding age at implantation, mental age, epilepsy syndrome, or epilepsy aetiology. The patients classified as responders had a slightly higher OC (mean OC: 1.9 mA) compared with non-responders (mean OC: 1.65 mA). Four patients became responders on normal cycling (30 s on-time, and 5 or 3 min off-time). Five patients who did not respond on normal cycling, became responders on rapid cycling (7 s on-time, and 12 or 18 s off-time), and three other patients became responders on intermediate cycling (21 or 14 s on-time, and 0.8-1.8 min off-time).
In 13 patients, the pulse width was increased from 250 to 500 ms in an attempt to achieve better seizure control. However, only one of these patients achieved some reduction in seizure frequency, but less than 50%. Six patients reported some seizure deterioration, and three patients reported adverse events on 500 ms. These side-effects stopped when the pulse width was returned to 250 ms.
Results from the questionnaires
According to answers from the questionnaire (caregivers of 34 patients), 22 patients had less severe seizures after VNS implantation, as both the seizures and the postictal periods were of shorter duration. In 12 patients the caregivers reported reduced use of benzodiazepines to terminate prolonged seizures. 13 patients were reported to have become more alert, and 13 patients were, according to their caregivers, in a better mood following VNS implantation. 19 patients reported some effect using the magnet (shorter, milder, or abortive seizures).
At follow-up, 14 patients were reported to have side-effects like voice change, mild dysphagia, or throat pain.
Discussion
In this study, 25% of the patient cohort was considered as VNS treatment responders, i.e. they had greater than 50% seizure reduction. However, no patients became seizure-free. The numbers were too small to reach firm conclusions about the effect of VNS in different patient sub-groups, e.g. different ages, different degrees of LD, and different epilepsy syndromes. But, also many patients without seizure reduction, reported that they nevertheless had some form of beneficial effect from the treatment. This included shorter seizures or postictal periods, less consumption of benzodiazepines, termination of seizures using the magnet, better mood, or they were more alert. This result concurs with results from other studies reporting an improvement in the quality of life as a consequence of VNS treatment. [10] [11] [12] [13] Our results are also in agreement with the findings from a longterm, prospective study in a similar population to ours. Huf et al. 13 performed at prospective study in 40 adult epilepsy patients with LD living in long-term care facilities, and found that after two years of VNS treatment, seizure frequency was reduced by at least 50% in 28% of the patients. However, Andriola and Vitale 14 demonstrated much better results in a retrospective study of 21 patients with LD (adults and children), with more than 50% seizure reduction in 68% of patients after six months follow-up.
There are several studies of the effect of VNS treatment in patients with Lennox-Gastaut syndrome or Lennox-Gastaut-like disorders. Five of these studies had a prospective design and disclosed a greater than 50% seizure reduction in 21-60% of children, 17, 18 and in 46-63% in mixed populations with both children and adults. 19, 20 However, Parker et al. 21, 22 followed 16 children with epileptic encephalopathies and found no significant improvement in seizure frequency during the first year, some improvement after two years, and then a subsequent deterioration during the third year of the study. Retrospective studies tend to show more promising results than prospective studies, with over 50% seizure reduction in 54-90% of children 11, 23, 24 and in 67% in a study of children and adults. 25 In some of these studies it is possible to compare patients with Lennox-Gastaut syndrome with patients with other forms of epilepsy, and these comparisons suggest that children with Lennox-Gastaut syndrome tend to have better results than patients with other epilepsy syndromes. 18, 23, 26 This might also be true for older patients, 20 and our results strengthen such an assumption. Previously, we have performed two studies at our centre on the efficacy and tolerability of VNS in unselected patients with difficult-to-control seizures. Nakken et al. 27 found that in a group of 47 adult patients 34% had greater than 50% seizure reduction after a mean follow-up period of 2.7 years. In this population, eight (17%) had a learning disability, and patients with Lennox-Gastaut syndrome experienced only a modest reduction in seizure frequency. In a study including 46 children, Bremer et al. 28 found a greater than 50% seizure reduction in 43% after a mean follow-up of 2.6 years. Included were 11 children with Lennox-Gastaut syndrome, and 45% of them achieved a greater than 50% seizure reduction. The current study is subject to certain limitations, and thus, the results should be interpreted with caution. Firstly, our centre is a tertiary referral centre, and patients recruited from such centres are usually the most difficult-to-treat, and therefore our patient group is subject to selection bias. Secondly, 2/3 of our cohort altered their AED treatment during the follow-up period; for an ideal research group AED treatment would have remained constant throughout the study period. However, as the patients previously had tried a mean of 10 AEDs, further adjustment of the dosing or drug regimens should not be expected to make a significant difference. Thirdly, our study is retrospective and uncontrolled, with all the limitations such a design implies.
Comparing different studies on the effects and tolerability of VNS is difficult due to variations in the populations studied and the follow-up time. Additionally, confounding factors are not always taken into consideration. The VNS-related studies from our centre indicate that VNS has a better seizure-reducing effect in children than adults. 27, 28 Andriola et al. 14 described a nine-year old patient, successfully treated with VNS for three years. When the device was explanted because of postoperative infection after battery change, the seizures did not increase, and therefore the device was therefore not re-implanted. This demonstrates that the natural history of epilepsy in some children can be benign and might perhaps explain why VNS has a better effect in children. Aldenkamp et al. 17 found that the VNS effect was most prominent in the group with the highest mental age at baseline, which suggests that learning disability might be a negative prognostic factor. However, VNS seems to have a seizure-reducing effect in patients with Lennox-Gastaut syndrome, which is at least similar to the effect reported in the rest of the epilepsy population, 25 and children with Lennox-Gastaut syndrome might experience a better effect than adults. Since our study was retrospective, it was not possible to assess whether there was a loss of VNS efficacy over time in some of the patients. Rossignol et al. 18 reported that four patients using VNS therapy who had an initial response at six months, lost seizure control after 24 months, and Parker et al. 22 demonstrated an increase in VNS efficacy for two years, but a loss of efficacy in the third year. Loss of efficacy after six months could indicate a placebo effect, and loss of efficacy after 24 months may suggest development of tolerance, similar to pharmacological tolerance. While VNS therapy offers some advantages, it also incurs some problems when treating patients with LD and epilepsy. One advantage is that VNS therapy does not result in interactions with AEDs or other medications. Further, as soon as the device is implanted, there are no problems with compliance. However, the varying degrees of cognitive and expressive abilities in this patient group mean that it is difficult to explain the concept of VNS and prepare the patients for the treatment procedures. Similarly, after implantation it is often difficult to evaluate the patients' tolerance to the different stimulation parameters. VNS therapy lacks measurable response parameters, equivalent to the serum concentrations of AEDs, with which to monitor and adjust the stimulation individually. However, although it might be assumed that postoperative infections could be a problem in a patient group that does not always treat their bandages with care, this problem was no more frequent in this study, with an infection rate of 4.3%, compared to 3-6% reported in other studies. 29, 30 One patient died in SUDEP after nine years of successful VNS treatment. About four months prior to death, she had fallen on ice, and had subsequently experienced a worsening of her seizure control. 3.5 months later, the VNS was explanted and a new one implanted. 11 days after the operation she was found dead. Investigations post mortem did not reveal any problems with the new stimulator, but the cable was twisted. In some studies SUDEP has been associated with changes in AED treatment, 31, 32 and it is possible there could be a parallel in VNS treatment, with increased risks of SUDEP related to abrupt changes in stimulation.
The utility of the magnet to abort seizures is limited in these patients, as many of them are unable to recognize and express the appearance of simple partial seizures/auras. However, relatives and carers are able to use the magnet during ongoing seizures, and in this study 56% reported some beneficial effect from using the magnet.
Conclusions
The results of this study indicate that VNS does not have the same favourable seizure-reducing effect in epilepsy patients with learning disabilities as the general epilepsy population. In our study, only 25% of the patients had >50% reduction in seizure frequency. The most challenging question to be addressed in future studies is which subgroups are likely to benefit the most from VNS treatment.
